Physician profile
Barbara Bellar
NPI 1447309208
$598,592.92
in general payments reported to CMS, 2019-2025
9 companies · $164K in 2025
The $164K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $34K · 2021: $26K · 2022: $42K · 2023: $120K · 2024: $177K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $461K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $461,212.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $461,212.88 | 2023-2025 | |
| Csl Behring | $125,571.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,799.99 | 2020 | |
| Shire North American Group INC | $5,799.99 | 2019 | |
| Glaxosmithkline, LLC. | $141.37 | 2019 | |
| Novo Nordisk INC | $20.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.49 | 2019 | |
| Amgen INC. | $14.97 | 2019 | |
| Lilly USA, LLC | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Bellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.